TP53 and myelodysplastic syndrome: APR-246 (eprenetapopt), a small molecule aiming at shifting mutant p53 towards a wild-type conformation, was recently tested together with azacitidine, in two phase 2 trials in patients with TP53 mutated AML and MDS with encouraging CR and OS rates [43, 44].